Table 4.
Results of Immunohistochemistry (Malignant Lesions).
| Diagnosis | Differentiation | Indexes |
Grade of Inflam | Percentage (%) |
||||
| P | G | H | PCNA | Glut-1 | HK-II | |||
| Primary (n = 41) | ||||||||
| Adenocarcinoma (n = 32) | Well-differentiated (n = 14) | 1.1 ± 1.4 | 0 | 1.4 ± 1.7 | 0.6 ± 0.9 | 18.4 ± 26.1 | 0 | 26.6 ± 33.4 |
| Moderately differentiated (n = 13) | 1.4 ± 1.4 | 1.0 ± 1.2 | 1.8 ± 1.3 | 0.7 ± 0.9 | 25.0 ± 27.0 | 17.8 ± 23.3 | 32.2 ± 25.2 | |
| Poorly differentiated (n = 5) | 2.0 ± 1.4 | 2.8 ± 1.9 | 3.0 ± 1.6 | 1.6 ± 1.1 | 38.6 ± 25.9 | 54.6 ± 37.5 | 58.6 ± 30.7 | |
| Total | 1.3 ± 1.3 | 0.9 ± 1.4 | 1.8 ± 1.5 | 0.8 ± 1.0 | 24.3 ± 26.5 | 15.8 ± 27.4 | 34.0 ± 31.0 | |
| SCC (n = 6) | Well-differentiated (n = 1) | 3 | 4 | 5 | 3 | 60 | 80 | 100 |
| Moderately differentiated (n = 5) | 2.4 ± 1.7 | 4.4 ± 0.9 | 2.2 ± 1.9 | 1.0 ± 1.4 | 48.0 ± 33.5 | 88.0 ± 17.9 | 41.2 ± 38.1 | |
| Total | 2.6 ± 1.4 | 4.5 ± 0.7 | 2.4 ± 1.7 | 0.8 ± 1.3 | 48.8 ± 30.0 | 88.9 ± 16.1 | 46.7 ± 36.5 | |
| Neuroendocrine | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Thymoma | - | 2 | 0 | 1 | 3 | 33 | 0 | 20 |
| Pleomorphic carc | Poorly differentiated | 1 | 2 | 0 | 1 | 20 | 33 | 0 |
| Metastatic (n = 5) | ||||||||
| Adenocarcinoma | Well-differentiated | 4 | 2 | 5 | 0 | 73 | 40 | 100 |
| SCC | Moderately differentiated | 5 | 3 | 4 | 0 | 100 | 60 | 73 |
| Renal Ca | Poorly differentiated | 2 | 1 | 5 | 1 | 40 | 20 | 100 |
| Esophageal Ca | Well-differentiated | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| PNET | - | 1 | 0 | 1 | 0 | 20 | 0 | 13 |
| Total (n = 46) | 1.6 ± 1.5 | 1.3 ± 1.8 | 1.9 ± 1.7 | 0.8 ± 1.0 | 29.5 ± 29.2 | 25.9 ± 35.2 | 36.3 ± 33.8 | |
Grade of Inflam = grade of inflammatory process in the specimen; Percentage = average percentage of anti-PCNA, anti-Glut-1, anti-HK-II antibody expression; P = P-index; G = G-index; H = H-index; SCC = squamous cell carcinoma; Ca = cancer; PNET = primary neuroendocrine tumor.